Fresenius (FRE) Credit presentation summary

Company structure and business overview

• Streamlined operations focus on Fresenius Kabi (pharma, biopharma, nutrition, MedTech) and Fresenius Helios (Europe’s leading private healthcare provider).

• Fresenius Kabi leads globally in IV drugs and parenteral nutrition, with strong positions in MedTech and biopharma.

• Fresenius Helios is the top hospital provider in Europe, with significant market shares in Germany and Spain.

Financial performance and growth

• FY 2025 group revenue reached €22.6bn, with 7% organic growth and EBIT of €2.6bn, up 6%.

• Core EPS grew 12% to €2.87, supported by strong operating results and reduced interest expenses.

• Net debt/EBITDA improved to 2.7x, reflecting strong cash flow and deleveraging.

• Q4 2025 saw 9% organic revenue growth and 13% EBIT growth, with a 12.1% EBIT margin.

Strategic initiatives and innovation

• Biopharma launches (e.g., tocilizumab, ustekinumab, denosumab) drive revenue and margin expansion.

• Digital transformation in Helios includes AI-based clinical decision support and digital patient engagement platforms.

• Portfolio rejuvenation and new product launches contributed over €500m in revenue and >20% EBIT margin in FY 2025.